SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ACADIA Pharmaceuticals Inc (ACAD) -- Ignore unavailable to you. Want to Upgrade?

To: mopgcw who wrote (269)4/19/2006 1:52:50 PM
From: LJM  Respond to of 588
 
Many thanks for the intrusion. I really am wondering why no mention in the news release re: SEPR.

I asked Rick on MOMO thread. He thinks no SEPR on this.

I sent IR the question and will post their response.



To: mopgcw who wrote (269)4/19/2006 1:56:23 PM
From: keokalani'nui  Read Replies (2) | Respond to of 588
 
My notes say:

Sepracor has an option for exclusive worldwide rights to develop and commercialize one preclinical compound from ACAD’s 5-HT2A program (5HT2 is a receptor related to deep sleep) for use in combination with eszopiclone, for sleep-related indications.

x-103 was in P2 before sepr collaboration (1/05).


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News